The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcoma
- PMID: 40217461
- PMCID: PMC11992814
- DOI: 10.1186/s12885-025-14050-x
The impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in patients with high-risk soft tissue sarcoma
Abstract
Background: The prognostic and predictive value of obesity and sarcopenia remains poorly defined in patients with high-risk soft tissue sarcoma (HR-STS). We sought to correlate clinical outcomes with CT-based body composition parameters in patients with HR-STS undergoing a multimodal preoperative therapy. The impact of radiologic and histopathologic response to preoperative treatment was correlated with individual fat and muscle distribution.
Methods: Patients with locally advanced non-abdominal HR-STS and treatment with preoperative chemotherapy + regional hyperthermia (RHT) +/- radiotherapy (RT) followed by surgery between 2015 and 2022 were retrospectively evaluated. Body composition parameters measured on baseline CT scans were correlated with clinical outcomes including event-free survival (EFS) and overall survival (OS) as well as radiologic and histopathologic treatment response.
Results: A total of 85 patients were included. Body composition parameters showed no significant correlation with radiologic or histopathologic treatment response. High total fat indices such as the total fat index (TFI, HR 3.56, p = 0.005) and high total fat to muscle ratio (FMR, HR 3.22, p = 0.020) were strongly associated with poor OS. Parameters for sarcopenia including skeletal muscle index (SMI) were not significantly linked to survival outcomes.
Conclusion: High fat indices and a high FMR are strong predictors of poor OS in patients with HR-STS. Larger studies are warranted to further clarify the prognostic impact of sarcopenia and the predictive value of body composition parameters on preoperative treatment response.
Keywords: Chemotherapy; EORTC-STBSG; Fat to muscle ratio; RECIST; Regional hyperthermia; Skeletal muscle index; Soft tissue sarcoma; Total fat index.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: The study was carried out in compliance with the Declaration of Helsinki. The Internal Review Board and the Ethical Review Committee at the Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, approved the protocol of this research project (Protocol Nr. 24–0976). Consent to participate: The need for informed consent was waived for this study by the Internal Review Board and the Ethical Review Committee at the Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, due to its retrospective design and irreversible anonymization of all data (Protocol Nr. 24–0976). Consent for publication: Not applicable. Disclosures: All co-authors have no relevant disclosures regarding this publication. Competing interests: The authors declare no competing interests.
Figures



Similar articles
-
LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment.BMC Cancer. 2025 Mar 18;25(1):496. doi: 10.1186/s12885-025-13889-4. BMC Cancer. 2025. PMID: 40102864 Free PMC article.
-
Opportunistic muscle measurements on staging chest CT for extremity and truncal soft tissue sarcoma are associated with survival.J Surg Oncol. 2020 Oct;122(5):869-876. doi: 10.1002/jso.26077. Epub 2020 Jul 1. J Surg Oncol. 2020. PMID: 32613648 Free PMC article.
-
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.BMC Cancer. 2019 Feb 12;19(1):134. doi: 10.1186/s12885-019-5319-8. BMC Cancer. 2019. PMID: 30744591 Free PMC article.
-
Sarcopenia and obesity among patients with soft tissue sarcoma - Association with clinicopathologic characteristics, complications and oncologic outcome: A systematic review and meta-analysis.Eur J Surg Oncol. 2021 Sep;47(9):2237-2247. doi: 10.1016/j.ejso.2021.04.024. Epub 2021 May 20. Eur J Surg Oncol. 2021. PMID: 34023166
-
Current trials and new aspects in soft tissue sarcoma of adults.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S4-8. doi: 10.1007/s00280-002-0445-3. Epub 2002 Apr 16. Cancer Chemother Pharmacol. 2002. PMID: 12042982 Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020. 10.3322/caac.21590. - PubMed
-
- Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–80. 10.1016/S1470-2045(16)00010-3. - PubMed
-
- Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus Ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 2014. 10.1016/S1470-2045(14)70063-4. - PubMed
-
- Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021. 10.1016/j.annonc.2021.07.006. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical